RENAL CONTINUUM: IS CKD REVERSIBLE?

renal continuum, chronic kidney illness, chronic kidney disease, chronic renal failure, regression of CKD, renoprotection

1. Anonymous. Part 1. Executive summary. Am J Kidney Dis 2002; 39 [Suppl. 1]: S17-S31

2. Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17

3. Hogg RJ, Furth S, Lemeley KV et al. Pediatrics 2003; 111 (6): 1416-1421

4. Смирнов АВ, Каюков ИГ, Есаян АМ и др. Превентивный подход в современной нефрологии. Нефрология 2004; 8(3): 7-14

5. Johnson CA et al. Clinical practice guidelines for chronic kidney disease in adults: Part I. Am Pham PhysicianSept.1, 2004; 70(5): 869-876

6. Johnson CA et al. Clinical practice guidelines for chronic kidney disease in adults: Part II. Am Pham Physician 2004; 70(6): 1091-1097

7. Somermeyer M. The disease-management approach to chronic kidney disease: A nephrologist’s perspective. Dial & Transplant 2005; 34 (11): 820-825

8. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15

9. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58(1): 353-362

10. Іванов ДД. Модифікація факторів ризику ХХН. Мистецтво лікування 2005; 8: 66-71

11. Иванов ДД. Выбор фармакотерапии при ХБП. Medicus Amicus 2005; 5: 28-29

12. 2nd Middle East & Africa Dialysis Forum: Conference Report. Dial & Transplant 2005; 34 (12): 883-896

13. Broe MED. Tubular regeneration and the role of bone marrow cells: «stem cell therapy» – a panacea? Nephrol Dial Transplant 2005; 20 (11): 2318-2320

14. Follow us. The Official ERAEDTA Newsletter. Year 1, Issue 3: 1-3

15. Wolf G. Zenon’s paradox or how much to lower blood pressure for optimal renoprotection. Nephrol Dial Transplant 2005; 20 (11): 2304-2307

16. Ivanov DD, Kushnirenko SV. Selective COX-2 inhibitor increase BRA II 1 +ACEI antiproteinuric effect in patients with metabolic syndrome. ERA-EDTA Congress, 2004. Abstract book: MP 134, P.274

17. Ivanov DD, Kushnirenko SV. BRA II 1 +ACEI vs BRA II 1 +ACEI+COX-2 inhibitor vs BRA II 1 +ACEI+Monoxidin in patients with diabetic nephropathy (DN). ERA-EDTA Congress, 2004. Abstract book: MP 119

18. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J 2004; 25: 1454-1470

19. FPIN’s Clinical Inquiries. Do ACE Inhibitors Decrease Mortality in Patients with Hypertension? Am Fam Phys 2004: 153-154

20. Karlamangla AS. Increases in serum non-high-density lipoprotein cholesterol may be beneficial in some high-functional older adults: MacArthur Studies of Successful Aging. J Am Geriartr Soc 2004; 52:487-94

21. Sharma AM, Hollander A, Koster J. Telmisartan in patients with mild/moderate hypertension and chronic renal disease (ESPIRIT study group). Clinical Nephrology 2005; 63 (4): 250-257

22. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptors blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 2005; 67: 799-812

23. Wu SC, Liu SP, Chiang HT, Lin SL. Prospective end randomized study of the antihypertensive effect and tolerability of three antihypertensive agents losartan, amlodipine and lisinopril in hypertensive patient. Heart Vessels 2004; 19 (1): 13-18.

24. www.nephrology.kiev.ua (Перший Український нефрологічний сайт)